C L Mackall

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Harnessing the biology of IL-7 for therapeutic application
    Crystal L Mackall
    Immunology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Nat Rev Immunol 11:330-42. 2011
  2. ncbi IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation
    C L Mackall
    Pediatric Oncology Branch and Experimental Immunology Branch, National Cancer Institute, Bethesda, MD, USA
    Blood 97:1491-7. 2001
  3. ncbi Targeting pediatric malignancies for T cell-mediated immune responses
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Oncol Rep 2:539-46. 2000
  4. ncbi Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
    C L Mackall
    Pediatric Oncology Branch, Medicine Branch, Experimental Immunology Branch, National Cancer Institute and Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, 20892 USA
    Blood 96:754-62. 2000
  5. ncbi T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Stem Cells 18:10-8. 2000
  6. ncbi T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncologist 4:370-8. 1999
  7. ncbi A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
    Crystal L Mackall
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1104, USA
    Clin Cancer Res 14:4850-8. 2008
  8. ncbi A potential role for interleukin-7 in T-cell homeostasis
    T J Fry
    Pediatric Oncology Branch, Biostatistics and Data Management Section, and HIV and AIDS Malignancy Branch of the National Cancer Institute, The National Institutes of Health, Bethesda, MD, USA
    Blood 97:2983-90. 2001
  9. ncbi Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy
    E C Wong
    Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, Bethesda, Maryland 20892, USA
    Cytotherapy 3:19-29. 2001
  10. ncbi Immune dysregulation in TGF-beta 1-deficient mice
    M Christ
    Cellular Immunology Section, Laboratory of Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
    J Immunol 153:1936-46. 1994

Detail Information

Publications24

  1. ncbi Harnessing the biology of IL-7 for therapeutic application
    Crystal L Mackall
    Immunology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Nat Rev Immunol 11:330-42. 2011
    ..This Review summarizes the biology of IL-7 and the results of its clinical use that are available so far to provide a perspective on the opportunities for clinical application of this cytokine...
  2. ncbi IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation
    C L Mackall
    Pediatric Oncology Branch and Experimental Immunology Branch, National Cancer Institute, Bethesda, MD, USA
    Blood 97:1491-7. 2001
    ..These results suggest that one mechanism by which T-cell-depleted hosts may support antigen-driven T-cell expansion in vivo is via an increased availability of T-cell-active cytokines to support clonal expansion...
  3. ncbi Targeting pediatric malignancies for T cell-mediated immune responses
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Oncol Rep 2:539-46. 2000
    ..The benefits and limitations for each approach, particularly as it pertains to the development of immunotherapy for pediatric tumors, are discussed in this article...
  4. ncbi Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
    C L Mackall
    Pediatric Oncology Branch, Medicine Branch, Experimental Immunology Branch, National Cancer Institute and Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, 20892 USA
    Blood 96:754-62. 2000
    ..Blood. 2000;96:754-762)..
  5. ncbi T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Stem Cells 18:10-8. 2000
    ....
  6. ncbi T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncologist 4:370-8. 1999
    ....
  7. ncbi A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
    Crystal L Mackall
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1104, USA
    Clin Cancer Res 14:4850-8. 2008
    ..This study administered a novel immunotherapy regimen aimed at consolidating remission in these patients...
  8. ncbi A potential role for interleukin-7 in T-cell homeostasis
    T J Fry
    Pediatric Oncology Branch, Biostatistics and Data Management Section, and HIV and AIDS Malignancy Branch of the National Cancer Institute, The National Institutes of Health, Bethesda, MD, USA
    Blood 97:2983-90. 2001
    ..In light of the known effects of IL-7 on T-cell regeneration, we postulate that increased availability of IL-7 could play a critical role in restoring T-cell homeostasis following T-cell depletion...
  9. ncbi Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy
    E C Wong
    Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, Bethesda, Maryland 20892, USA
    Cytotherapy 3:19-29. 2001
    ..This method avoids the use of FBS and results in immature DCs suitable for clinical trials...
  10. ncbi Immune dysregulation in TGF-beta 1-deficient mice
    M Christ
    Cellular Immunology Section, Laboratory of Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
    J Immunol 153:1936-46. 1994
    ..The mechanism leading to T cell anergy remains unclear; however, these data confirm the essential role for TGF-beta 1 in maintaining normal immune function...
  11. ncbi Thymic function in young/old chimeras: substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Eur J Immunol 28:1886-93. 1998
    ..Therefore, thymic function is reduced with aged but it is not lost, suggesting that therapeutic approaches to enhance thymic function may be successful even in very aged hosts...
  12. ncbi Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression
    J J Letterio
    The Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 5055, USA
    J Clin Invest 98:2109-19. 1996
    ..Thus, MHC class II antigens are essential for the expression of autoimmunity in TGF-beta1-deficient mice, and normally may cooperate with TGF-beta1 to regulate hematopoiesis...
  13. ncbi Thymic aging and T-cell regeneration
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1928, USA
    Immunol Rev 160:91-102. 1997
    ..The development of therapies which can reverse thymic aging are critical for improving outcome in clinical settings of T-cell depletion, and could potentially improve immunologic function in normal aged hosts...
  14. ncbi Interleukin-7 restores immunity in athymic T-cell-depleted hosts
    T J Fry
    Molecular Oncology Section, Pediatric Branch, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
    Blood 97:1525-33. 2001
    ..These results show that immune competence for even stringent antigens such as HY can be restored in the absence of thymic function and identify IL-7 as a potent modulator of thymic-independent T-cell regeneration...
  15. ncbi Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy
    C L Mackall
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1928, USA
    Immunol Rev 157:61-72. 1997
    ..New strategies to enhance thymic function in man after BMT would hold great therapeutic potential...
  16. ncbi Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction
    M E Merino
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    J Clin Oncol 19:3649-59. 2001
    ..We used a new approach to purge artificially contaminated cellular specimens of Ewing's sarcoma and show the capacity for real-time polymerase chain reaction (PCR) to quantify the contamination level of Ewing's sarcoma in such specimens...
  17. ncbi Modulating T-cell homeostasis with IL-7: preclinical and clinical studies
    C M Capitini
    Immunology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Intern Med 266:141-53. 2009
    ..This review will address current understanding of IL-7 biology, review recent clinical experiences and discuss potential future clinical applications of IL-7, or IL-7 blockade, in the setting of disease...
  18. ncbi Clinical trial designs for the early clinical development of therapeutic cancer vaccines
    R M Simon
    Branch of Biometric Research, Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7434, USA
    J Clin Oncol 19:1848-54. 2001
    ..Several conclusions for expediting the clinical development of effective cancer vaccines are proposed...
  19. ncbi A role for TGFbeta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFbeta1 null mice
    T A Borkowski
    Dermatology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Clin Invest 100:575-81. 1997
    ....
  20. ncbi Interleukin-7: master regulator of peripheral T-cell homeostasis?
    T J Fry
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, MSC 1928, Bethesda, MD 20892-1928, USA
    Trends Immunol 22:564-71. 2001
    ....
  21. ncbi Enhancing immune reconstitution after stem cell transplants with cytokines
    C L Mackall
    Pediatric Branch NCI, Bethesda, MD 20892, USA
    Cytotherapy 4:427-8. 2002
  22. ncbi Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future
    T J Fry
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Bone Marrow Transplant 35:S53-7. 2005
    ..New translatable strategies are needed to safely augment one or both of these pathways in the setting of allogeneic hematopoietic progenitor cell transplantation...
  23. ncbi Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine
    S Jankelevich
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 183:1116-20. 2001
    ..CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression...
  24. ncbi Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders
    A B Kulkarni
    Molecular and Medical Genetics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892
    Am J Pathol 146:264-75. 1995
    ....